Matches in SemOpenAlex for { <https://semopenalex.org/work/W4284703618> ?p ?o ?g. }
Showing items 1 to 59 of
59
with 100 items per page.
- W4284703618 endingPage "11" @default.
- W4284703618 startingPage "1" @default.
- W4284703618 abstract "Background: Apremilast is an oral, selective phosphodiesterase-4 (PDE-4) enzyme inhibitor, approved by the US-FDA for management of moderate to severe plaque psoriasis. Apremilast belongs to class of drug that function by modulating pro-inflammatory cytokines and have a low molecular weight (<1 kD), identified as small molecules. Due to its convenience in administration via oral or topical route, adequate efficacy, great safety profile and low cost they are emerging as treatment choices in inflammatory dermatosis and other systemic inflammatory disorders. 
 Material and Methods: A hospital based, prospective, interventional, cohort study was conducted on 78 patients with Chronic plaque psoriasis. Efficacy of Apremilast was studied in 38 patients receiving oral Apremilast with topical steroids in comparison to 36 patients who were given only topical steroids for 16 weeks. Patients were evaluated pre-treatment and then every 4 weeks for a period of 16 weeks and followed up to the 28th week for any adverse effects associated with apremilast therapy. Outcome was assessed on the basis of PASI score and clinical photographs. Side effects in both groups were recorded.
 Results: Primary endpoint (PASI75 and above) was achieved in 68.42% patients in group A. Among this patient's PASI 90 was achieved in 13.16% (n=5) and PASI 100 was obtained in 13.16% (n=5). In Group B, none of the patients achieved PASI 75. Most common side effects observed in group A were GI disturbances. No significant adverse effect was noted in group B.
 Conclusion: Apremilast has good efficacy and safety in patients with chronic plaque psoriasis. and is generally well tolerated which makes it possible to keep other immunosuppressants to be kept in reserve for more severe stages of disease. Our study supports the favorable benefit:risk profile of oral apremilast." @default.
- W4284703618 created "2022-07-08" @default.
- W4284703618 creator A5008657632 @default.
- W4284703618 creator A5055003143 @default.
- W4284703618 creator A5060313982 @default.
- W4284703618 creator A5061731176 @default.
- W4284703618 creator A5069632155 @default.
- W4284703618 date "2022-07-05" @default.
- W4284703618 modified "2023-10-14" @default.
- W4284703618 title "Clinical Efficacy and Safety of Oral Apremilast: Treatment Analysis for Chronic Plaque Psoriasis" @default.
- W4284703618 doi "https://doi.org/10.9734/jpri/2022/v34i43b36316" @default.
- W4284703618 hasPublicationYear "2022" @default.
- W4284703618 type Work @default.
- W4284703618 citedByCount "0" @default.
- W4284703618 crossrefType "journal-article" @default.
- W4284703618 hasAuthorship W4284703618A5008657632 @default.
- W4284703618 hasAuthorship W4284703618A5055003143 @default.
- W4284703618 hasAuthorship W4284703618A5060313982 @default.
- W4284703618 hasAuthorship W4284703618A5061731176 @default.
- W4284703618 hasAuthorship W4284703618A5069632155 @default.
- W4284703618 hasBestOaLocation W42847036181 @default.
- W4284703618 hasConcept C126322002 @default.
- W4284703618 hasConcept C16005928 @default.
- W4284703618 hasConcept C197934379 @default.
- W4284703618 hasConcept C203092338 @default.
- W4284703618 hasConcept C2776260265 @default.
- W4284703618 hasConcept C2780564577 @default.
- W4284703618 hasConcept C2781427535 @default.
- W4284703618 hasConcept C3020604521 @default.
- W4284703618 hasConcept C535046627 @default.
- W4284703618 hasConcept C71924100 @default.
- W4284703618 hasConceptScore W4284703618C126322002 @default.
- W4284703618 hasConceptScore W4284703618C16005928 @default.
- W4284703618 hasConceptScore W4284703618C197934379 @default.
- W4284703618 hasConceptScore W4284703618C203092338 @default.
- W4284703618 hasConceptScore W4284703618C2776260265 @default.
- W4284703618 hasConceptScore W4284703618C2780564577 @default.
- W4284703618 hasConceptScore W4284703618C2781427535 @default.
- W4284703618 hasConceptScore W4284703618C3020604521 @default.
- W4284703618 hasConceptScore W4284703618C535046627 @default.
- W4284703618 hasConceptScore W4284703618C71924100 @default.
- W4284703618 hasLocation W42847036181 @default.
- W4284703618 hasOpenAccess W4284703618 @default.
- W4284703618 hasPrimaryLocation W42847036181 @default.
- W4284703618 hasRelatedWork W2178857336 @default.
- W4284703618 hasRelatedWork W2185164199 @default.
- W4284703618 hasRelatedWork W2338797462 @default.
- W4284703618 hasRelatedWork W2398457950 @default.
- W4284703618 hasRelatedWork W2400036265 @default.
- W4284703618 hasRelatedWork W2792899302 @default.
- W4284703618 hasRelatedWork W2904182792 @default.
- W4284703618 hasRelatedWork W3108657795 @default.
- W4284703618 hasRelatedWork W3195838575 @default.
- W4284703618 hasRelatedWork W4313815515 @default.
- W4284703618 isParatext "false" @default.
- W4284703618 isRetracted "false" @default.
- W4284703618 workType "article" @default.